Atossa Therapeutics (ATOS) said Wednesday that the US Patent and Trademark Office granted a new patent covering highly pure and stable enteric oral formulations of (Z)-endoxifen, a breast cancer treatment
The patent includes 58 claims, encompassing various formulations and therapeutic methods for hormone-dependent breast and reproductive tract disorders, the company said.
Atossa shares rose 1.9% in recent Wednesday trading.
Price: 0.81, Change: +0.02, Percent Change: +1.89
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。